Skip to main content
. 2020 Dec 13;12(12):3748. doi: 10.3390/cancers12123748

Figure 3.

Figure 3

Effect of CM414 treatment on liver injury and fibrosis in Mdr2-KO mice. (a) aiagram showing the treatment schedule of Mdr2-KO mice. Animals received a daily i.p. injection of vehicle or CM414 (40 mg/kg body weight) five days per week for 4 weeks, when animals were sacrificed, and serum and liver tissue samples were analyzed. (b) liver-to-body weight ratio (expressed as %) in WT mice and in Mdr2-KO mice treated with vehicle or CM414. (c) serum transaminases (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and alkaline phosphatase (ALP) levels in WT and Mdr2-KO mice treated with vehicle or with CM414. (d) representative images of Sirius Red staining for collagen and immunostaining for α-SMA, CD34, and CK19 in liver sections from WT and Mdr2-KO mice treated with vehicle or with CM414. Graphs on the right show the corresponding quantification of positively stained areas. * p < 0.05. ** p < 0.01. *** p < 0.001.